Search

Your search keyword '"Wege, Henning"' showing total 388 results

Search Constraints

Start Over You searched for: Author "Wege, Henning" Remove constraint Author: "Wege, Henning"
388 results on '"Wege, Henning"'

Search Results

2. Efficacy and safety of palliative treatment in patients with autoimmune liver disease-associated hepatocellular carcinoma

3. Nanoliposomal irinotecan and fluorouracil plus leucovorin versus fluorouracil plus leucovorin in patients with cholangiocarcinoma and gallbladder carcinoma previously treated with gemcitabine-based therapies (AIO NALIRICC): a multicentre, open-label, randomised, phase 2 trial

5. Impact of body mass index in patients receiving atezolizumab plus bevacizumab for hepatocellular carcinoma

6. Characteristics and outcomes of immunotherapy-related liver injury in patients with hepatocellular carcinoma versus other advanced solid tumours

7. A meta-analysis and real-world cohort study on the sex-related differences in efficacy and safety of immunotherapy for hepatocellular carcinoma

8. THU-464 aMAP score predicts progression-free survival in patients receiving atezolizumab plus bevacizumab for hepatocellular carcinoma

9. OS-027-YI Immune checkpoint profiles on circulating extracellular vesicles predict response to immunotherapy in heptaocellular carcinoma

12. Gastroesophageal Oncology Highlights from the European Society for Medical Oncology Annual Meeting 2023

13. Colorectal Cancer Highlights from the European Society for Medical Oncology Annual Meeting 2023

17. Assessing the impact of COVID-19 on liver cancer management (CERO-19)

19. Autoreninnen und Autoren

20. Immunotherapy vs Best Supportive Care for Patients With Hepatocellular Cancer With Child-Pugh B Dysfunction

22. NASH limits anti-tumour surveillance in immunotherapy-treated HCC

23. GALAD Score Detects Early Hepatocellular Carcinoma in an International Cohort of Patients With Nonalcoholic Steatohepatitis

24. Pancreatic, Hepatic, and Biliary Tract Oncology Highlights from the European Society for Medical Oncology Annual Meeting 2023

25. S3-Leitlinie „Diagnostik und Therapie biliärer Karzinome“ – Kurzversion

26. S3-Leitlinie „Diagnostik und Therapie biliärer Karzinome“ – Langversion 4.0

27. S3-Leitlinie „Diagnostik und Therapie des Hepatozellulären Karzinoms“ – Kurzversion

28. S3-Leitlinie „Diagnostik und Therapie des Hepatozellulären Karzinoms“ – Langversion 4.0

29. A meta-analysis and real-world cohort study on the sex-related differences in efficacy and safety of immunotherapy for hepatocellular carcinoma

30. Autoren

32. Doxorubicin-loaded nanoparticles for patients with advanced hepatocellular carcinoma after sorafenib treatment failure (RELIVE): a phase 3 randomised controlled trial

33. Efficacy and safety of atezolizumab/bevacizumab in patients with HCC after prior systemic therapy: A global, observational study

36. Validation of the CRAFITY score in patients with hepatocellular carcinoma treated with atezolizumab and bevacizumab

37. The ALBI grade refines prognostic prediction in advanced hepatocellular cancer and enables risk stratification for bleeding events following atezolizumab plus bevacizumab

38. Efficacy and tolerability of atezolizumab and bevacizumab in patients with hepatocellular carcinoma previously treated with systemic therapy: a global, observational study

39. Dynamic evolution of the serum metabolome reflects human hepatocarcinogenesis

40. Feasibility of systemic anti-cancer therapy as an alternative to best supportive care in patients with advanced HCC and Child-Pugh B liver dysfunction

41. Transarterial chemoembolization and systemic treatment in patients with autoimmune liver disease-associated hepatocellular carcinoma: outcome and safety profile

45. Genetic variants in PNPLA3 and TM6SF2 predispose to the development of hepatocellular carcinoma in individuals with alcohol-related cirrhosis

50. S3-Leitlinie Diagnostik und Therapie biliärer Karzinome

Catalog

Books, media, physical & digital resources